Q1 2023 EPS Estimates for Surmodics, Inc. (NASDAQ:SRDX) Boosted by Analyst

Surmodics, Inc. (NASDAQ:SRDXGet Rating) – Equities researchers at Barrington Research lifted their Q1 2023 earnings per share estimates for shares of Surmodics in a research report issued to clients and investors on Thursday, July 28th. Barrington Research analyst M. Petusky now anticipates that the company will post earnings of $1.06 per share for the quarter, up from their prior estimate of $0.99. The consensus estimate for Surmodics’ current full-year earnings is ($1.15) per share.

Separately, TheStreet lowered Surmodics from a “c” rating to a “d” rating in a report on Friday, April 29th.

Surmodics Stock Performance

Shares of SRDX opened at $34.80 on Friday. The stock has a 50 day moving average price of $37.22 and a two-hundred day moving average price of $40.40. The firm has a market capitalization of $486.85 million, a P/E ratio of -46.40 and a beta of 1.05. Surmodics has a 52 week low of $32.43 and a 52 week high of $62.27.

Surmodics (NASDAQ:SRDXGet Rating) last issued its quarterly earnings data on Wednesday, April 27th. The company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.10. The firm had revenue of $26.11 million during the quarter, compared to analyst estimates of $24.40 million. Surmodics had a negative return on equity of 6.22% and a negative net margin of 10.80%. During the same period in the previous year, the company posted $0.62 EPS.

Institutional Trading of Surmodics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Sphinx Trading LP bought a new position in shares of Surmodics during the fourth quarter valued at approximately $39,000. KBC Group NV bought a new stake in shares of Surmodics during the second quarter valued at approximately $41,000. Captrust Financial Advisors increased its position in shares of Surmodics by 24.3% during the first quarter. Captrust Financial Advisors now owns 2,307 shares of the company’s stock valued at $105,000 after acquiring an additional 451 shares in the last quarter. Hsbc Holdings PLC bought a new stake in shares of Surmodics during the first quarter valued at approximately $225,000. Finally, MetLife Investment Management LLC increased its position in shares of Surmodics by 58.1% during the first quarter. MetLife Investment Management LLC now owns 7,505 shares of the company’s stock valued at $340,000 after acquiring an additional 2,758 shares in the last quarter. 94.40% of the stock is currently owned by hedge funds and other institutional investors.

Surmodics Company Profile

(Get Rating)

Surmodics, Inc, together with its subsidiaries, provides surface modification technologies for intravascular medical devices, and chemical components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates in two segments, Medical Device and In Vitro Diagnostics (IVD).

Read More

Earnings History and Estimates for Surmodics (NASDAQ:SRDX)

Receive News & Ratings for Surmodics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surmodics and related companies with MarketBeat.com's FREE daily email newsletter.